600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)

60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)

100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)

Histologically negative is defined as no malignant cells present in the axillary lymph nodes during surgery.

Disease-free survival is defined as the time from date of study enrollment (randomization) to first date of progressive disease (PD) or death from any cause. PD per Response Evaluation Criteria In Solid Tumors (RECIST) criteria is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. For patients not known to have died as of the data cut-off date and who do not have progressive disease, disease-free survival was censored at the last contact date.

Total of all reporting groups

cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)

The number of participants with a clinical tumor response based on measurement of tumor size after the first sequence of chemotherapy, without a second confirmatory tumor measurement, per protocol.

Participants meeting following criteria qualify for clinical tumor response:

• Histologic diagnosis of primary operable breast cancer
• No concurrent antitumor therapy up to surgery
• Presence of measurable disease as defined by RECIST.
• Treatment with at least one dose of study drug of assigned study regimen.

The number of participants with a clinical tumor response based on measurement of tumor size after the second sequence of chemotherapy, without a second confirmatory tumor measurement required, per protocol.

Participants meeting following criteria qualify for clinical tumor response:

• Histologic diagnosis of primary operable breast cancer
• No concurrent antitumor therapy up to surgery
• Presence of measurable disease as defined by RECIST.
• Treatment with at least one dose of study drug of assigned study regimen.

Histologically negative is defined as no malignant cells present in the axillary lymph nodes during surgery.

Participants meeting the following criteria qualify for pathological tumor response:

• Histologic diagnosis of primary operable breast cancer
• No concurrent antitumor therapy
• Specimen for evaluation of pathological response obtained upon surgery
• Treatment with at least one dose of study drug of the assigned study regimen.

Disease-free survival is defined as the time from date of study enrollment (randomization) to first date of progressive disease (PD) or death from any cause. PD per Response Evaluation Criteria In Solid Tumors (RECIST) criteria is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. For patients not known to have died as of the data cut-off date and who do not have progressive disease, disease-free survival was censored at the last contact date.

All randomized participants. In the Pemetrexed plus Doxorubicin, Followed by Docetaxel arm, 99 participants were censored. In the Cyclophosphamide plus Doxorubicin, Followed by Docetaxel arm, 94 participants were censored.

cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)